Skip to main content
Fig. 1 | Biomarker Research

Fig. 1

From: Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis

Fig. 1

Objective responses of target lesions following treatment with lenvatinib plus anti-PD-1 antibodies. a Overall change from baseline in tumor size according to INV assessment. b Overall change from baseline in tumor size according to IIR assessment. Each bar represents one patient. Red bars represent patients whose responses were classified as PD due to the appearance of new lesions

Back to article page

Biomarker Research

ISSN: 2050-7771

Contact us